NextCure Price Target Maintained With a $4.00/Share by Needham
NextCure Analyst Ratings
Piper Sandler Maintains NextCure(NXTC.US) With Buy Rating, Maintains Target Price $3
Piper Sandler Keeps Their Buy Rating on NextCure (NXTC)
Buy Rating for NextCure Supported by Promising Clinical Results and Strong Financial Position
Needham Maintains NextCure(NXTC.US) With Buy Rating, Maintains Target Price $4
NextCure Analyst Ratings
HC Wainwright & Co. Reiterates Buy on NextCure, Maintains $8 Price Target
NextCure Analyst Ratings
HC Wainwright & Co. Reiterates Buy on NextCure, Maintains $8 Price Target
Buy Rating Affirmed on NextCure's NC410 Promising Clinical Outcomes in MSS-CRC and Ovarian Cancer
Needham: Reiterates the NextCure (NXTC.US) rating and adjusted from buy to buy rating, target price is $4.00.
NextCure Analyst Ratings
Buy Rating Affirmed for NextCure Amid Promising Oncology Treatment Prospects and Solid Financials
Promising Clinical Outlook for NextCure's Novel ADC LNCB74 Spurs Buy Rating
NextCure Analyst Ratings
Promising Clinical Trial Results for NextCure's NC410 Bolster Buy Rating
Needham Maintains Buy on NextCure, Maintains $4 Price Target
Analysts Offer Insights on Healthcare Companies: Femasys (FEMY) and NextCure (NXTC)
Needham Maintains Buy on NextCure, Lowers Price Target to $4